These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22171072)

  • 61. [Pemetrexed].
    Sudoh J; Gemma A
    Gan To Kagaku Ryoho; 2008 Jun; 35(6):1033-8. PubMed ID: 18633241
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Update of pemetrexed in thoracic oncology].
    Brechot JM; Morère JF
    Bull Cancer; 2007; 94 Spec No Actualites():S139-41. PubMed ID: 17845984
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
    Wang YY; Zhang H; Bai H; Wang SH; Wu MN; An TT; Zhao J; Zhuo ML; Duan JC; Wang ZJ; Wang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):162-8. PubMed ID: 23856136
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacology and mechanism of action of pemetrexed.
    Adjei AA
    Clin Lung Cancer; 2004 Apr; 5 Suppl 2():S51-5. PubMed ID: 15117425
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair.
    Bulgar AD; Weeks LD; Miao Y; Yang S; Xu Y; Guo C; Markowitz S; Oleinick N; Gerson SL; Liu L
    Cell Death Dis; 2012 Jan; 3(1):e252. PubMed ID: 22237209
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cortactin expression: Association with disease progression and survival in oral squamous cell carcinoma.
    Horn D; Gross M; Dyckhoff G; Fuchs J; Grabe N; Weichert W; Herpel E; Herold-Mende C; Lichter P; Hoffmann J; Hess J; Freier K
    Head Neck; 2018 Dec; 40(12):2685-2694. PubMed ID: 30456890
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens.
    Hainsworth JD; Cebotaru CL; Kanarev V; Ciuleanu TE; Damyanov D; Stella P; Ganchev H; Pover G; Morris C; Tzekova V
    J Thorac Oncol; 2010 Oct; 5(10):1630-6. PubMed ID: 20802351
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Second-line pemetrexed treatment in Taiwanese patients with advanced nonsmall cell lung cancer: an open-label single-arm study.
    Chang GC; Tsai CM; Hsia TC; Yang CH; Abdulnabi R; Blair JM; Linn C
    J Formos Med Assoc; 2013 Sep; 112(9):518-26. PubMed ID: 24060197
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
    Socinski MA; Smit EF; Lorigan P; Konduri K; Reck M; Szczesna A; Blakely J; Serwatowski P; Karaseva NA; Ciuleanu T; Jassem J; Dediu M; Hong S; Visseren-Grul C; Hanauske AR; Obasaju CK; Guba SC; Thatcher N
    J Clin Oncol; 2009 Oct; 27(28):4787-92. PubMed ID: 19720897
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Schuette WH; Gröschel A; Sebastian M; Andreas S; Müller T; Schneller F; Guetz S; Eschbach C; Bohnet S; Leschinger MI; Reck M
    Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A genome-wide association study identified AFF1 as a susceptibility locus for systemic lupus eyrthematosus in Japanese.
    Okada Y; Shimane K; Kochi Y; Tahira T; Suzuki A; Higasa K; Takahashi A; Horita T; Atsumi T; Ishii T; Okamoto A; Fujio K; Hirakata M; Amano H; Kondo Y; Ito S; Takada K; Mimori A; Saito K; Kamachi M; Kawaguchi Y; Ikari K; Mohammed OW; Matsuda K; Terao C; Ohmura K; Myouzen K; Hosono N; Tsunoda T; Nishimoto N; Mimori T; Matsuda F; Tanaka Y; Sumida T; Yamanaka H; Takasaki Y; Koike T; Horiuchi T; Hayashi K; Kubo M; Kamatani N; Yamada R; Nakamura Y; Yamamoto K
    PLoS Genet; 2012 Jan; 8(1):e1002455. PubMed ID: 22291604
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Can pemetrexed help in malignant mesothelioma?
    Drug Ther Bull; 2006 Oct; 44(10):77-80. PubMed ID: 17067119
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene.
    Capiaux GM; Budak-Alpdogan T; Alpdogan O; Bornmann W; Takebe N; Banerjee D; Maley F; Bertino JR
    Cancer Gene Ther; 2004 Dec; 11(12):767-73. PubMed ID: 15359285
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma.
    Anraku M; Tagawa T; Wu L; Yun Z; Keshavjee S; Zhang L; Johnston MR; de Perrot M
    J Immunol; 2010 Jul; 185(2):956-66. PubMed ID: 20548032
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO‑cGMP signaling in lung adenocarcinoma cells in vitro and in vivo.
    Nagai H; Yasuda H; Hatachi Y; Xue D; Sasaki T; Yamaya M; Sakamori Y; Togashi Y; Masago K; Ito I; Kim YH; Mio T; Mishima M
    Int J Oncol; 2012 Jul; 41(1):24-30. PubMed ID: 22552400
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Phase I trial of vinflunine and pemetrexed in refractory solid tumors.
    Sanoff HK; Davies J; Walko C; Buie L; Chiu WK; Ivanova A; O'Neil B; Stinchcombe TE; Keller K; Dees EC
    Invest New Drugs; 2011 Feb; 29(1):131-6. PubMed ID: 19830387
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience.
    Bearz A; Talamini R; Rossoni G; Santo A; de Pangher V; Fasola G; Rosetti F; Favaretto A; Gregorc V; Berretta M; Santarossa S; Berto E; Tirelli U
    BMC Res Notes; 2012 Sep; 5():482. PubMed ID: 22943698
    [TBL] [Abstract][Full Text] [Related]  

  • 78. MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.
    Yamamoto K; Seike M; Takeuchi S; Soeno C; Miyanaga A; Noro R; Minegishi Y; Kubota K; Gemma A
    Oncol Rep; 2014 Dec; 32(6):2365-72. PubMed ID: 25231602
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition.
    Racanelli AC; Rothbart SB; Heyer CL; Moran RG
    Cancer Res; 2009 Jul; 69(13):5467-74. PubMed ID: 19549896
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Systemic treatments for mesothelioma: standard and novel.
    Kindler HL
    Curr Treat Options Oncol; 2008 Jun; 9(2-3):171-9. PubMed ID: 18770046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.